- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01241357
High-Tc Susceptometer to Monitor Transfusional Iron Overload
High-Tc Susceptometer to Monitor Transfusional Iron Overload (NSR Device)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This project will validate our new high-transition-temperature (high-Tc; operating at 77°K, cooled by liquid nitrogen) superconducting magnetic susceptometer as the most clinically effective means for monitoring iron overload in patients who require chronic red blood cell transfusion. Transfusional iron overload is an orphan disease that develops in patients who require regular blood transfusions for treatment of a variety of refractory anemias that are themselves orphan disorders, including sickle-cell disease, thalassemia major (Cooley's anemia), Diamond-Blackfan anemia, aplastic anemia, pure red cell aplasia, hypoplastic and myelodysplastic disorders. In the United States, the number of anemic patients with transfusional iron overload is estimated to be less than 50,000. Without iron-chelating therapy, potentially lethal amounts of iron accumulate in these patients. Because the body lacks an effective means to eliminate excess iron, the iron contained in transfused red cells is progressively deposited in the liver, heart, pancreas and other organs. Cirrhosis, heart failure, diabetes and other disorders develop. Treatment with a chelating agent capable of sequestering iron and permitting its excretion from the body provides a means of managing transfusional iron overload that can prolong survival and avert or ameliorate iron-induced organ damage. Two iron-chelating agents are now approved for use in the U.S. for the treatment of transfusional iron overload: (1) deferoxamine B (Desferal®), a parenteral agent in use for almost four decades, and (ii) deferasirox (Exjade®), an orally administered agent introduced in 2005. With both chelators, optimal management of patients requires careful monitoring of body iron to prevent iron-induced toxicity while avoiding adverse effects of excessive chelator administration. Our laboratories originally proposed that storage iron (ferritin and hemosiderin) could be non-invasively assessed in vivo by measurement of magnetic susceptibility. We subsequently developed low-transition-temperature (low-Tc; operating at 4°K, cooled by liquid helium) superconducting quantum interference device (SQUID) susceptometry as a clinical method for quantitation of hepatic iron stores. The transition temperature is the temperature at which the electrical resistance of a superconducting material drops to zero. The safety, ease, rapidity and comfort of magnetic measurements have made frequent, serial investigations technically feasible and practically acceptable to patients. Susceptometry permits accurate, direct, reliable, and repeated measurements of hepatic iron stores. Despite these advantages, the cost (about $1,000,000 per device), instrumental complexity and need for liquid-helium cooling of the low-Tc susceptometers restricted clinical adoption of the method. Worldwide, only four low-Tc susceptometers have been used clinically (in New York, Oakland, Hamburg and Turin). Recently, with the support of a Bioengineering Research Partnership Grant (R01 DK057209), we have made a series of technological breakthroughs and instrumental innovations that have made possible replacement, redesign and refinement of the elements of the low-Tc susceptometer, operating at 4°K in liquid helium, with components able to function at 77°K in liquid nitrogen. This new high-Tc susceptometer, the first medical device utilizing the phenomenon of high-temperature superconductivity, is an inexpensive instrument that can easily be used in a hospital environment. These Phase 2 clinical studies are designed to test the hypothesis that measurements of hepatic iron stores with our new high-Tc susceptometer are clinically superior to all other available methods and to supply essential data needed for FDA approval of the medical device. The proposed project has three specific aims:
- to calibrate the high-Tc susceptometer with the results of biochemical analysis of tissue from liver explants from adult and pediatric patients undergoing liver transplantation and from clinically indicated liver biopsy; and
- to prospectively validate the high-Tc susceptometer using the results of biochemical analysis of tissue from liver explants from adult and pediatric patients undergoing liver transplantation and from clinically indicated liver biopsy; and
- to prospectively compare measurements of hepatic iron concentration by the high-Tc susceptometer with (i) estimates derived from liver magnetic resonance imaging (MRI) relaxation rates (R2, R2*, signal intensity ratios), (ii) with determinations of serum ferritin, and (iii) with histopathological examination, using biochemical analysis of liver storage iron concentrations as the reference standard.
FDA approval of an affordable, readily usable instrument for the non-invasive measurement of hepatic iron stores would lead to major advances in the management of patients with transfusional iron overload that would find immediate and widespread clinical use both in the U.S. and worldwide.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- being an adult male, nonpregnant female or child who is scheduled for liver transplantation, has transfusional iron overload or is healthy with no known disorder affecting body iron stores,
- being of sufficient size for the susceptometer (about 15 kg body weight),
- being able to lie quietly during the measurement procedure (about 5 to 10 minutes),
- being either able to give fully informed consent or, if a minor, with a parent or legal guardian who is able to give fully informed consent for participation of the minor.
Exclusion Criteria:
- any form of magnetic contamination or electrical device which cannot be removed for the magnetic measurement procedure, including jewelry, pacemakers, artificial joints, metal staples, indwelling catheters with metallic components, dental braces or other magnetic objects;
- obesity, ascites or other conditions in which the liver to surface distance exceeds 25 mm;
- pregnancy, treatment for mental illness, imprisonment, institutionalization, or any condition that impairs ability to provide fully informed consent.
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Observation only
This study has a single arm and no intervention.
|
Subjects will first have an ultrasound study to determine the location of the liver and measure the distance from skin surface to the liver.
Subjects will then be examined with the high Tc susceptometer to determine the amount of iron in the liver.
The entire procedure will usually take one-half hour or less.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hepatic non-heme iron concentration determined by biomagnetic susceptometry
Time Frame: 2 years
|
The primary study analysis will be a comparison of the results of measurements of the hepatic storage iron concentration by biomagnetic susceptometry with the results of biochemical analysis of the storage iron concentration in liver tissue.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum ferritin concentration
Time Frame: 2 years
|
A secondary study analysis will be a comparison of the results of measurements of the hepatic storage iron concentration by biomagnetic susceptometry with the results of measurements of the serum ferritin concentration.
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gary M. Brittenham, M.D., Columbia University
Publications and helpful links
General Publications
- Farrell DE, Allen CJ, Whilden MW, Kidane TK, Baig TN, Tripp JH, Brown RW, Sheth A, Brittenham GM. A new instrument designed to measure the magnetic susceptibility of human liver tissue in vivo. IEEE Trans Magnetics 2007;43:3543-3554.
- Farrell DE, Allen CJ, Whilden MW, Tripp JH, Usoskin A, Sheth A, Brittenham GM. Magnetic measurement of liver iron stores: engineering aspects of a new scanning susceptometer based on high temperature superconductivity. IEEE Trans Magnetics 2007; 43:4030-4036.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Bone Marrow Diseases
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Iron Metabolism Disorders
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Bone Marrow Failure Disorders
- Myelodysplastic Syndromes
- Iron Overload
- Anemia, Sickle Cell
- Thalassemia
- beta-Thalassemia
- Anemia, Aplastic
Other Study ID Numbers
- AAAE5051
- R01FD003702 (U.S. FDA Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndromes
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
National Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
GCP-Service International West GmbHSaint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaboratorsNot yet recruitingLow Risk Myelodysplastic SyndromesSpain, Poland, Italy, Germany, France
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
I-Mab Biopharma Co. Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
SCRI Development Innovations, LLCNovartis PharmaceuticalsTerminated
Clinical Trials on Hepatic biomagnetic susceptibility measurement
-
Federico II UniversityRecruitingHepatocellular CarcinomaItaly
-
Medical University of ViennaUnknownErectile Dysfunction | CirrhosisAustria
-
McGill University Health Centre/Research Institute...RecruitingCirrhosis | Portal Hypertension | Chronic Liver DiseaseCanada
-
VA Connecticut Healthcare SystemCompleted
-
Leiden University Medical CenterUniversitaire Ziekenhuizen KU Leuven; Academisch Medisch Centrum - Universiteit... and other collaboratorsUnknownLiver Cirrhosis | Acute Bleeding Esophageal VaricesNetherlands, Belgium
-
German Institute of Human NutritionCompletedWildtype | Polymorphism Liver FABPGermany
-
Seoul National University Boramae HospitalCompletedLiver Cirrhosis | Hepatocellular CarcinomaKorea, Republic of
-
University of Ljubljana, Faculty of MedicineCompletedStress | Type 1 DiabetesSlovenia
-
Emory UniversityTerminated
-
Universidade Federal do Rio de JaneiroNot yet recruitingPortal Hypertension | Idiopathic Non-Cirrhotic Portal Hypertension | Non-Cirrhotic Portal Hypertension | Vascular Disorder of Liver | Non-Cirrhotic Portal Fibrosis | Regenerative Nodular Hyperplasia | Incomplete Septal Cirrhosis | Obliterative Portal Venopathy | Hepatoportal Sclerosis | Idiopathic Portal...Brazil